Cargando…

Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial

OBJECTIVE: We investigated whether single nucleotide polymorphisms (SNPs) associated with neuroplasticity and activity of monoamine neurotransmitters, such as the brain-derived neurotrophic factor (BDNF, rs6265), the serotonin transporter (SLC6A4, rs25531), the tryptophan hydroxylase 1 (TPH1, rs1800...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunoni, Andre R., Carracedo, Angel, Amigo, Olalla M., Pellicer, Ana L., Talib, Leda, Carvalho, Andre F., Lotufo, Paulo A., Benseñor, Isabela M., Gattaz, Wagner, Cappi, Carolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Psiquiatria 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115450/
https://www.ncbi.nlm.nih.gov/pubmed/31721892
http://dx.doi.org/10.1590/1516-4446-2019-0620
_version_ 1783514100155809792
author Brunoni, Andre R.
Carracedo, Angel
Amigo, Olalla M.
Pellicer, Ana L.
Talib, Leda
Carvalho, Andre F.
Lotufo, Paulo A.
Benseñor, Isabela M.
Gattaz, Wagner
Cappi, Carolina
author_facet Brunoni, Andre R.
Carracedo, Angel
Amigo, Olalla M.
Pellicer, Ana L.
Talib, Leda
Carvalho, Andre F.
Lotufo, Paulo A.
Benseñor, Isabela M.
Gattaz, Wagner
Cappi, Carolina
author_sort Brunoni, Andre R.
collection PubMed
description OBJECTIVE: We investigated whether single nucleotide polymorphisms (SNPs) associated with neuroplasticity and activity of monoamine neurotransmitters, such as the brain-derived neurotrophic factor (BDNF, rs6265), the serotonin transporter (SLC6A4, rs25531), the tryptophan hydroxylase 1 (TPH1, rs1800532), the 5-hydroxytryptamine receptor 2A (HTR2A, rs6311, rs6313, rs7997012), and the catechol-O-methyltransferase (COMT, rs4680) genes, are associated with efficacy of transcranial direct current stimulation (tDCS) in major depression. METHODS: Data from the Escitalopram vs. Electrical Current Therapy for Treating Depression Clinical Study (ELECT-TDCS) were used. Participants were antidepressant-free at baseline and presented with an acute, moderate-to-severe unipolar depressive episode. They were randomized to receive escitalopram/tDCS-sham (n=75), tDCS/placebo-pill (n=75), or placebo-pill/sham-tDCS (n=45). General linear models assessed the interaction between treatment group and allele-wise carriers. Additional analyses were performed for each group and each genotype separately. RESULTS: Pairwise group comparisons (tDCS vs. placebo, tDCS vs. escitalopram, and escitalopram vs. placebo) did not identify alleles associated with depression improvement. In addition, exploratory analyses also did not identify any SNP unequivocally associated with improvement of depression in any treatment group. CONCLUSION: Larger, combined datasets are necessary to identify candidate genes for tDCS response.
format Online
Article
Text
id pubmed-7115450
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Associação Brasileira de Psiquiatria
record_format MEDLINE/PubMed
spelling pubmed-71154502020-04-03 Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial Brunoni, Andre R. Carracedo, Angel Amigo, Olalla M. Pellicer, Ana L. Talib, Leda Carvalho, Andre F. Lotufo, Paulo A. Benseñor, Isabela M. Gattaz, Wagner Cappi, Carolina Braz J Psychiatry Original Article OBJECTIVE: We investigated whether single nucleotide polymorphisms (SNPs) associated with neuroplasticity and activity of monoamine neurotransmitters, such as the brain-derived neurotrophic factor (BDNF, rs6265), the serotonin transporter (SLC6A4, rs25531), the tryptophan hydroxylase 1 (TPH1, rs1800532), the 5-hydroxytryptamine receptor 2A (HTR2A, rs6311, rs6313, rs7997012), and the catechol-O-methyltransferase (COMT, rs4680) genes, are associated with efficacy of transcranial direct current stimulation (tDCS) in major depression. METHODS: Data from the Escitalopram vs. Electrical Current Therapy for Treating Depression Clinical Study (ELECT-TDCS) were used. Participants were antidepressant-free at baseline and presented with an acute, moderate-to-severe unipolar depressive episode. They were randomized to receive escitalopram/tDCS-sham (n=75), tDCS/placebo-pill (n=75), or placebo-pill/sham-tDCS (n=45). General linear models assessed the interaction between treatment group and allele-wise carriers. Additional analyses were performed for each group and each genotype separately. RESULTS: Pairwise group comparisons (tDCS vs. placebo, tDCS vs. escitalopram, and escitalopram vs. placebo) did not identify alleles associated with depression improvement. In addition, exploratory analyses also did not identify any SNP unequivocally associated with improvement of depression in any treatment group. CONCLUSION: Larger, combined datasets are necessary to identify candidate genes for tDCS response. Associação Brasileira de Psiquiatria 2019-11-11 /pmc/articles/PMC7115450/ /pubmed/31721892 http://dx.doi.org/10.1590/1516-4446-2019-0620 Text en http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Brunoni, Andre R.
Carracedo, Angel
Amigo, Olalla M.
Pellicer, Ana L.
Talib, Leda
Carvalho, Andre F.
Lotufo, Paulo A.
Benseñor, Isabela M.
Gattaz, Wagner
Cappi, Carolina
Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial
title Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial
title_full Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial
title_fullStr Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial
title_full_unstemmed Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial
title_short Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial
title_sort association of bdnf, htr2a, tph1, slc6a4, and comt polymorphisms with tdcs and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115450/
https://www.ncbi.nlm.nih.gov/pubmed/31721892
http://dx.doi.org/10.1590/1516-4446-2019-0620
work_keys_str_mv AT brunoniandrer associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial
AT carracedoangel associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial
AT amigoolallam associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial
AT pelliceranal associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial
AT talibleda associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial
AT carvalhoandref associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial
AT lotufopauloa associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial
AT bensenorisabelam associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial
AT gattazwagner associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial
AT cappicarolina associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial